Cardiol Therapeutics is a nanotherapeutics company focusing on research and commercial development of proprietary drug formulations for the treatment of heart failure and cancer. Co. produces pharmaceutical cannabidiol ("CBD") products and develops innovative therapies for heart disease, including acute myocarditis and other causes of heart failure. Co.'s lead product, CardiolRx, is designed to be the safest and most consistent CBD formulation on the market. CardiolRx is pharmaceutically produced, cGMP certified, and does not contain any THC. The CRDL average annual return since 2021 is shown above.
The Average Annual Return on the CRDL average annual return since 2021 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether CRDL average annual return since 2021 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the CRDL average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|